Charles River ( CRL ) International Revenue Performance Explored
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS ...
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics - Dyadic International ( NASDAQ:DYAI )
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- ERS Genomics Limited ( 'ERS' ) , the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today ...
This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Jack Henry & Associates ( NASDAQ:JKHY ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Robinhood To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday - Bentley Systems ( NASDAQ:BSY ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised Kratos Defense & Security Solutions, Inc. ( NASDAQ:KTOS ) price target from $80 to $95.
Charles River ( CRL ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 9:00 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Charles River Beat Expectations But Why Is The Stock Falling? - Charles River ( NYSE:CRL )
Charles River Laboratories International Inc. ( NYSE:CRL ) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company's strategic review.
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Charles River Laboratories ( CRL ) Q3 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +4.74% and +2.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Solventum ( SOLV ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories ( CRL ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Will Charles River ( CRL ) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
Why Charles River Stock May Struggle In Its Final Phase - Charles River ( NYSE:CRL )
Charles River Laboratories International Inc. ( NYSE:CRL ) is entering a critical point in its 18-phase Adhishthana cycle. The stock currently sits in Phase 17 on the weekly chart, with Phase 18, its final phase, set to begin on October 20. Here's how the cycle has unfolded so far and what the ...
Pediatrix Medical Group, Inc. ( MD ) Soars to 52-Week High, Time to Cash Out?
Pediatrix Medical Group (MD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CRL Stock Rises Following New Strategic Oncology Collaborations
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Charles River ( NYSE:CRL ) , Dick's Sporting Goods ( NYSE:DKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst David Windley upgraded Charles River Laboratories International, Inc.
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Danaher Gains From Business Strength Amid Persisting Headwinds
DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.
Charles River Stock May Benefit From Joining EASYGEN Consortium
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Interpreting Charles River ( CRL ) International Revenue Trends
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Charles River ( CRL ) Q2 EPS Jumps 11%
Charles River Laboratories International ( NYSE:CRL ) , a global provider of laboratory services and research models for drug development, announced its latest earnings results on August 6, 2025. The company reported GAAP revenue of $1,032.1 million, slightly up 0.6% year-over-year ( GAAP ) , and ...
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Charles River ( NYSE:CRL )
Q2 adjusted EPS of $3.12 beat estimates of $2.50, rising 11.4% year over year. FY25 EPS outlook raised to $9.90-$10.30 vs. prior guidance of $9.30-$9.80 The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. Charles River Laboratories ...
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Charles River Laboratories ( CRL ) Q2 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Organon ( OGN ) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AMN Healthcare Services ( AMN ) to Report a Decline in Earnings: What to Look Out for
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare Analytical Testing Services Market is expected to generate a revenue of USD 9.56 Billion by 2031, Globally, at 11.20% CAGR: Verified Market Research®
Lewes, Delaware, July 31, 2025 ( GLOBE NEWSWIRE ) -- The Global Healthcare Analytical Testing Services Market Size is projected to grow at a CAGR of 11.20% from 2024 to 2031, according to a new report published by Verified Market Research®.
Charles River Laboratories ( CRL ) Expected to Beat Earnings Estimates: Should You Buy?
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On Thursday - Arrive AI ( NASDAQ:ARAI ) , ASGN ( NYSE:ASGN )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Thursday. Shares of RPM International Inc. RPM rose sharply on Thursday following better-than-expected quarterly EPS and sales.
Will Charles River ( CRL ) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Bloom Energy ( NYSE:BE ) , Charles River ( NYSE:CRL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101 - Liminatus Pharma ( NASDAQ:LIMN )
La Palma, CA June 24, 2025 -- ( PR.com ) -- Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy.
Shoals Technologies Group, Inc. Appoints Industry Veteran, Bobbie L. King, Jr., as Chief Legal Officer
PORTLAND, Tenn., June 16, 2025 ( GLOBE NEWSWIRE ) -- Shoals Technologies Group, Inc. ( "Shoals" ) , a leading provider of electrical balance of system solutions for the global energy transition market, announced today that it has further strengthened its executive team with the addition of ...
Shoals Technologies Group, Inc. Appoints Industry Veteran, Bobbie L. King, Jr., as Chief Legal Officer - Shoals Technologies Gr ( NASDAQ:SHLS ) , HASI ( NYSE:HASI )
PORTLAND, Tenn., June 16, 2025 ( GLOBE NEWSWIRE ) -- Shoals Technologies Group, Inc. ( "Shoals" ) , a leading provider of electrical balance of system solutions for the global energy transition market, announced today that it has further strengthened its executive team with the addition of ...
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Why Is Charles River ( CRL ) Down 0.1% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
This Waste Management Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Charles River ( NYSE:CRL ) , Macerich ( NYSE:MAC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wolfe Research analyst Andrew Rosivach upgraded the rating for Newmark Group, Inc.
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Understanding Charles River ( CRL ) Reliance on International Revenue
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value
The firm has three possible paths toward value creation at the drug development company.
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization - Charles River ( NYSE:CRL )
Adjusted EPS rose to $2.34, beating estimates and up from $2.27 YoY. Revenue hit $984.2 million, beating consensus of $941.97 million despite a 2.7% YoY decline. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday - Angi ( NASDAQ:ANGI ) , BorgWarner ( NYSE:BWA )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Rockwell Automation, Inc. ROK rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS ...
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Charles River Laboratories ( CRL ) Beats Q1 Earnings and Revenue Estimates
Charles River (CRL) delivered earnings and revenue surprises of 13.59% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
Company to use facility to further development of RetinalGenix's therapies for neurodegenerative and retinal diseases Company to use facility to further development of RetinalGenix's therapies for neurodegenerative and retinal diseases ...
